by Don Gibbons | May 25, 2023
A recent Wall Street Journal article reminded me of the work of someone I came to know well while at the California Institute for Regenerative Medicine (CIRM): Jeanne Loring of the Scripps Research Institute. The article detailed a cell therapy for Parkinson’s Disease...
by Cal Strode | May 18, 2023
Regular readers of Alliance for Regenerative Medicine (ARM) sector reports may have noticed that the organization is taking a new approach to sharing insights on the cell and gene therapy sector. In April, ARM launched a new format for distilling key data and trend...
by Cal Strode | Apr 27, 2023
The first Science Huddle panel discussion of 2023, Cell & Gene Therapy: Maximizing Commercialization, delved into challenges keeping leaders in the cell and gene therapy (CGT) commercialization space up at night. Moderating the event was Dr. Christian K....
by Sara M. Nolte | Apr 18, 2023
One of the major limitations of using stem cell donors is the challenge of finding an adequate match, which is why I always get excited about therapies that use a patient’s own tissue. But why is the issue of a “match” such a big deal? You may have come across terms...
by Cal Strode | Mar 29, 2023
Few people have made bigger contributions to the Canadian regenerative medicine ecosystem than Dr. Peter Zandstra. He is co-founder of two companies advancing cutting-edge biotechnologies for therapeutic use (Notch Therapeutics and ExCellThera, both of which are...
Comments